SCHEMBL1471552

SCHEMBL1471552

Oc1c2cccc1Cc1cccc(c1O)Cc1cccc(c1O)Cc1cccc(c1O)C2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
CYP3A4 P08684 3/20 0.48
HSD17B10 Q99714 3/20 0.48
TSHR P16473 2/20 0.48
ALOX15 P16050 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
MEN1 O00255 1/20 0.48
USP2 O75604 1/20 0.48
HPN P05981 1/20 0.48
ALOX5 P09917 1/20 0.48
MAPT P10636 1/20 0.48
THRB P10828 1/20 0.48
PTGS1 P23219 1/20 0.48
PDE4A P27815 1/20 0.48
KDR P35968 1/20 0.48
KMT2A Q03164 1/20 0.48
SIRT5 Q9NXA8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
HRH3 Q9Y5N1 1/20 0.48
CA2 P00918 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2471777 1.00 ALDH1A1 (0.48) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL29383145 1.00 ALDH1A1 (0.48) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL12168748 1.00 ALDH1A1 (0.48) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL29644944 1.00 ALDH1A1 (0.48) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL29366399 1.00 ALDH1A1 (0.48) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL29469562 1.00 ALDH1A1 (0.48) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL19113839 0.91 TSHR (0.43) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL13821762 0.87 ALDH1A1 (0.42) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL14507604 0.87 CYP3A4 (0.40) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL13894504 0.87 ALDH1A1 (0.40) ALDH1A1CYP3A4HSD17B10TSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4580489-A1 DEVICES AND METHODS FOR MEASURING A CONCENTRATION OF A TARGET ANALYTE IN A BIOLOGICAL FLUID IN VIVO DexCom, Inc. (US) 2025-07-09 EP claimed
WO-2024050124-A1 DEVICES AND METHODS FOR MEASURING A CONCENTRATION OF A TARGET ANALYTE IN A BIOLOGICAL FLUID IN VIVO DEXCOM, INC. (US) 2024-03-07 WO claimed
US-20240074682-A1 DEVICES AND METHODS FOR MEASURING A CONCENTRATION OF A TARGET ANALYTE IN A BIOLOGICAL FLUID IN VIVO DEXCOM, INC. (US) 2024-03-07 US claimed
US-20220249411-A1 CALIXARENE COMPOUNDS AND USES THEREOF Universität Wien (AT) 2022-08-11 US claimed
EP-4633804-A1 PROCESS FOR PREPARING ALPHA,BETA-UNSATURATED CARBONYL COMPOUND Firmenich SA (CH) 2025-10-22 EP disclosed
EP-4580489-A1 DEVICES AND METHODS FOR MEASURING A CONCENTRATION OF A TARGET ANALYTE IN A BIOLOGICAL FLUID IN VIVO DexCom, Inc. (US) 2025-07-09 EP disclosed
EP-4531681-A1 SYSTEMS AND METHODS FOR OPTIMIZING TREATMENT USING PHYSIOLOGICAL PROFILES Dexcom, Inc. (US) 2025-04-09 EP disclosed
EP-4531680-A1 SENSING SYSTEMS AND METHODS FOR DIAGNOSING KIDNEY DISEASE Dexcom, Inc. (US) 2025-04-09 EP disclosed
EP-4531679-A1 SYSTEMS AND METHODS FOR MONITORING, DIAGNOSIS, AND DECISION SUPPORT FOR DIABETES IN PATIENTS WITH KIDNEY DISEASE Dexcom, Inc. (US) 2025-04-09 EP disclosed
EP-4482383-A1 SENSING SYSTEMS AND METHODS FOR PROVIDING DECISION SUPPORT AROUND KIDNEY HEALTH AND/OR DIABETES Dexcom, Inc. (US) 2025-01-01 EP disclosed
WO-2024126769-A1 PROCESS FOR PREPARING ALPHA,BETA-UNSATURATED CARBONYL COMPOUND FIRMENICH SA (CH) 2024-06-20 WO disclosed
EP-3119610-B1 ENCRYPTED OPTICAL MARKERS FOR SECURITY APPLICATIONS APDN BVI INC (VG) 2024-05-22 EP disclosed
WO-2009078371-A2 PROCESS FOR PRODUCING CARBON MATERIAL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-25 WO disclosed
US-7282083-B2 Methods, systems, and uses for calixarenes BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2007-10-16 US disclosed
US-20070215839-A1 Molecular actuators, and methods of use thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2007-09-20 US disclosed
US-7271259-B1 Solid phase host compositions NORTHWESTERN UNIVERSITY (US) 2007-09-18 US disclosed
US-20050063861-A1 Methods, systems, and uses for calixarenes BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2005-03-24 US disclosed
WO-2004056708-A1 MATERIAL FOR THE REMOVAL OF POLLUTANTS UNIVERSITY OF SURREY (GB) 2004-07-08 WO disclosed
US-5641684-A Ion-sensitive dyes JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) 1997-06-24 US disclosed
EP-0572599-A1 ION-SENSITIVE DYES KODAK LIMITED (GB) 1993-12-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070215839-A1 Molecular actuators, and methods of use thereof NOD2, PIEZO1, TPR ALDH1A1 4481/4885CYP3A4 2410/4885HSD17B10 4759/4885
US-20220249411-A1 CALIXARENE COMPOUNDS AND USES THEREOF GPX1, LPO, CALR ALDH1A1 259/4885CYP3A4 1632/4885HSD17B10 804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.